Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Autoimmune Disorders

  Free Subscription

Articles published in Acta Neurol Scand

Retrieve available abstracts of 51 articles:
HTML format

Single Articles

    June 2022
  1. HAYAT S, Asad A, Hasan I, Jahan I, et al
    Nucleotide oligomerization domain polymorphism confers no risk to Guillain-Barre syndrome.
    Acta Neurol Scand. 2022 Jun 2. doi: 10.1111/ane.13649.
    PubMed     Abstract available

    May 2022
  2. OZAKBAS S, Piri Cinar B, Baba C, Kosehasanogullari G, et al
    Self-injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real-world cohort.
    Acta Neurol Scand. 2022;145:557-564.
    PubMed     Abstract available

    April 2022
  3. ZHAO YY, Wang HX, Wang M, Yuan B, et al
    Relapse factors of patients of anti-N-methyl-D-aspartate receptor encephalitis.
    Acta Neurol Scand. 2022;145:434-441.
    PubMed     Abstract available

  4. SUN Y, Ren G, Ren J, Shan W, et al
    The prognosis of late-onset anti-N-methyl-D-aspartate receptor encephalitis in China.
    Acta Neurol Scand. 2022;145:449-455.
    PubMed     Abstract available

  5. CABREIRA V, Dias L, Fernandes B, Aires A, et al
    Tocilizumab for severe refractory primary central nervous system vasculitis: A center experience.
    Acta Neurol Scand. 2022;145:479-483.
    PubMed     Abstract available

    March 2022
    Comment on comorbidities in older patients with myasthenia gravis.
    Acta Neurol Scand. 2022 Mar 20. doi: 10.1111/ane.13606.

    February 2022
  7. PARK JS, Eah KY, Park JM
    Epidemiological profile of myasthenia gravis in South Korea using the national health insurance database.
    Acta Neurol Scand. 2022 Feb 9. doi: 10.1111/ane.13596.
    PubMed     Abstract available

    Very late onset of myasthenia gravis. Comment: Comorbidities in older patients with myasthenia gravis.
    Acta Neurol Scand. 2022 Feb 7. doi: 10.1111/ane.13588.

    January 2022
  9. WELD-BLUNDELL IV, Grech L, Learmonth YC, Marck CH, et al
    Lifestyle and complementary therapies in multiple sclerosis guidelines: Systematic review.
    Acta Neurol Scand. 2022 Jan 17. doi: 10.1111/ane.13574.
    PubMed     Abstract available

  10. SOBIESZCZUK E, Napiorkowski L, Szczudlik P, Kostera-Pruszczyk A, et al
    Myasthenia gravis-treatment and severity in nationwide cohort.
    Acta Neurol Scand. 2022 Jan 4. doi: 10.1111/ane.13576.
    PubMed     Abstract available

    Neurological side effects of SARS-CoV-2 vaccinations.
    Acta Neurol Scand. 2022;145:5-9.
    PubMed     Abstract available

    December 2021
  12. LAHOZ FERNANDEZ PE, Miranda Pereira J, Fonseca Risso I, Baleeiro Rodrigues Silva P, et al
    Guillain-Barre syndrome following COVID-19 vaccines: A scoping review.
    Acta Neurol Scand. 2021 Dec 29. doi: 10.1111/ane.13575.
    PubMed     Abstract available

    November 2021
  13. SMYRKE N, Dunn N, Murley C, Mason D, et al
    Standardized mortality ratios in multiple sclerosis: Systematic review with meta-analysis.
    Acta Neurol Scand. 2021 Nov 24. doi: 10.1111/ane.13559.
    PubMed     Abstract available

  14. THEODORSDOTTIR A, Larsen PV, Nielsen HH, Illes Z, et al
    Multiple sclerosis impairment scale and brain MRI in secondary progressive multiple sclerosis.
    Acta Neurol Scand. 2021 Nov 19. doi: 10.1111/ane.13554.
    PubMed     Abstract available

  15. CHAABAN L, Safwan N, Moussa H, El-Sammak S, et al
    Central vein sign: A putative diagnostic marker for multiple sclerosis.
    Acta Neurol Scand. 2021 Nov 18. doi: 10.1111/ane.13553.
    PubMed     Abstract available

  16. KLIMIEC-MOSKAL E, Quirke M, Leite MI
    Comorbidities in older patients with myasthenia gravis - Comparison between early- and late-onset disease.
    Acta Neurol Scand. 2021 Nov 8. doi: 10.1111/ane.13549.
    PubMed     Abstract available

  17. CONTRERAS JP, Salinas R, Vidal C, Hoffmeister L, et al
    Validation of Spanish version of 15-item myasthenia gravis quality-of-life questionnaire.
    Acta Neurol Scand. 2021;144:546-552.
    PubMed     Abstract available

    October 2021
  18. LANGESKOV-CHRISTENSEN M, Hvid LG, Jensen HB, Nielsen HH, et al
    Efficacy of high-intensity aerobic exercise on common multiple sclerosis symptoms.
    Acta Neurol Scand. 2021 Oct 22. doi: 10.1111/ane.13540.
    PubMed     Abstract available

    September 2021
  19. KAUR H, Sureshbabu S, Mittal GK, Joseph M, et al
    Catastrophic health expenditure in patients with Guillain Barre syndrome: Retrospective study.
    Acta Neurol Scand. 2021 Sep 1. doi: 10.1111/ane.13523.
    PubMed     Abstract available

    August 2021
  20. MARIC G, Pekmezovic T, Tamas O, Veselinovic N, et al
    Impact of comorbidities on the disability progression in multiple sclerosis.
    Acta Neurol Scand. 2021 Aug 20. doi: 10.1111/ane.13516.
    PubMed     Abstract available

  21. TELJAS C, Bostrom I, Marrie RA, Landtblom AM, et al
    Validating the diagnosis of multiple sclerosis using Swedish administrative data in Varmland County.
    Acta Neurol Scand. 2021 Aug 6. doi: 10.1111/ane.13514.
    PubMed     Abstract available

    July 2021
  22. JOHANSSON K, Wasling P, Axelsson M
    Fatigue, insomnia and daytime sleepiness in multiple sclerosis versus narcolepsy.
    Acta Neurol Scand. 2021 Jul 19. doi: 10.1111/ane.13497.
    PubMed     Abstract available

    June 2021
  23. ZHUKOVSKY C, Herman S, Wiberg A, Cunningham JL, et al
    Urokinase, CX3CL1, CCL2, TRAIL and IL-18 induced by interferon-beta treatment.
    Acta Neurol Scand. 2021;143:602-607.
    PubMed     Abstract available

    May 2021
  24. LANDTBLOM AM, Berntsson SG, Bostrom I, Iacobaeus E, et al
    Multiple sclerosis and COVID-19: The Swedish experience.
    Acta Neurol Scand. 2021 May 24. doi: 10.1111/ane.13453.
    PubMed     Abstract available

  25. TARAKCI E, Tarakci D, Hajebrahimi F, Budak M, et al
    Supervised exercises versus telerehabilitation. Benefits for persons with multiple sclerosis.
    Acta Neurol Scand. 2021 May 7. doi: 10.1111/ane.13448.
    PubMed     Abstract available

    April 2021
  26. FEASEL CD, Sandroff BM, Motl RW
    Aerobic reserve capacity in multiple sclerosis-Preliminary evidence.
    Acta Neurol Scand. 2021 Apr 29. doi: 10.1111/ane.13441.
    PubMed     Abstract available

  27. SAIED Z, Rachdi A, Thamlaoui S, Nabli F, et al
    Myasthenia gravis and COVID-19: A case series and comparison with literature.
    Acta Neurol Scand. 2021 Apr 29. doi: 10.1111/ane.13440.
    PubMed     Abstract available

    March 2021
  28. DONSKOV AO, Vinge L, Axelsen SM, Andersen H, et al
    Overactive bladder in patients with myasthenia gravis-A cross-sectional population-based study.
    Acta Neurol Scand. 2021 Mar 27. doi: 10.1111/ane.13419.
    PubMed     Abstract available

  29. KAVALIUNAS A, Danylaite Karrenbauer V, Hillert J
    Socioeconomic consequences of multiple sclerosis-A systematic literature review.
    Acta Neurol Scand. 2021 Mar 22. doi: 10.1111/ane.13411.
    PubMed     Abstract available

    February 2021
  30. OLSSON A, Gustavsen S, Gisselo Lauridsen K, Chenoufi Hasselbalch I, et al
    Neutrophil-to-lymphocyte ratio and CRP as biomarkers in multiple sclerosis: A systematic review.
    Acta Neurol Scand. 2021 Feb 16. doi: 10.1111/ane.13401.
    PubMed     Abstract available

    December 2020
  31. TEKEOGLU A, Yeldan I, Ozdincler AR, Saip S, et al
    The efficiency of mirror therapy on drop foot in Multiple Sclerosis Patients.
    Acta Neurol Scand. 2020 Dec 3. doi: 10.1111/ane.13385.
    PubMed     Abstract available

  32. RYLTOFT AK, Al-Zuhairy A, Sindrup SH, Andersen H, et al
    Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin.
    Acta Neurol Scand. 2020;142:637-640.
    PubMed     Abstract available

    November 2020
  33. NI G, Lin W, Cai X, Qin J, et al
    Associations between seizures and MRI in patients with anti-NMDAR encephalitis.
    Acta Neurol Scand. 2020;142:460-465.
    PubMed     Abstract available

  34. BORGSTROM M, Tisell A, Link H, Wilhelm E, et al
    Retinal thinning and brain atrophy in early MS and CIS.
    Acta Neurol Scand. 2020;142:418-427.
    PubMed     Abstract available

    September 2020
  35. TRIPATHI M, St AR, Ihtisham K, Garg A, et al
    Metabolic scoring in Autoimmune Epilepsy-Should APE scores be modified?
    Acta Neurol Scand. 2020 Sep 16. doi: 10.1111/ane.13346.
    PubMed     Abstract available

  36. CHESHMAVAR M, Mirmosayyeb O, Badihian N, Badihian S, et al
    Rituximab and glatiramer-acetate in secondary-progressive multiple sclerosis: A randomized-clinical trial.
    Acta Neurol Scand. 2020 Sep 8. doi: 10.1111/ane.13344.
    PubMed     Abstract available

    August 2020
  37. CHEN J, Shang W, Chen Y, Li Y, et al
    Thymomatous Myasthenia Gravis: 10-year Experience of a Single Center.
    Acta Neurol Scand. 2020 Aug 6. doi: 10.1111/ane.13332.
    PubMed     Abstract available

  38. WONG VT, So H, Lam TT, Yip RM, et al
    Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies.
    Acta Neurol Scand. 2020 Aug 6. doi: 10.1111/ane.13331.
    PubMed     Abstract available

  39. JONS D, Zetterberg H, Malmestrom C, Bergstrom T, et al
    Intrathecal immunoreactivity in people with or without previous infectious mononucleosis.
    Acta Neurol Scand. 2020;142:161-168.
    PubMed     Abstract available

    July 2020
  40. WANDELL P, Fredrikson S, Carlsson AC, Li X, et al
    Multiple sclerosis among first- and second-generation immigrant groups in Sweden.
    Acta Neurol Scand. 2020 Jul 10. doi: 10.1111/ane.13314.
    PubMed     Abstract available

  41. VECCHIO D, Varrasi C, Virgilio E, Spagarino A, et al
    Cannabinoids in multiple sclerosis: A neurophysiological analysis.
    Acta Neurol Scand. 2020 Jul 6. doi: 10.1111/ane.13313.
    PubMed     Abstract available

    June 2020
  42. LAHDENPERA S, Soilu-Hanninen M, Kuusisto HM, Atula S, et al
    Medication adherence/persistence among patients with active multiple sclerosis in Finland.
    Acta Neurol Scand. 2020 Jun 19. doi: 10.1111/ane.13301.
    PubMed     Abstract available

  43. NING P, Yang B, Yang X, Zhao Q, et al
    A nomogram to predict mechanical ventilation in Guillain-Barre syndrome patients.
    Acta Neurol Scand. 2020 Jun 4. doi: 10.1111/ane.13294.
    PubMed     Abstract available

  44. PIRTTISALO AL, Soilu-Hanninen M, Sumelahti ML, Krokki O, et al
    Changes in multiple sclerosis epidemiology in Finland over five decades.
    Acta Neurol Scand. 2020 Jun 4. doi: 10.1111/ane.13295.
    PubMed     Abstract available

  45. NEPAL G, Shing YK, Yadav JK, Rehrig JH, et al
    Efficacy and safety of rituximab in autoimmune encephalitis: a meta-analysis.
    Acta Neurol Scand. 2020 Jun 2. doi: 10.1111/ane.13291.
    PubMed     Abstract available

    May 2020
  46. MAMOEI S, Hvid LG, Boye Jensen H, Zijdewind I, et al
    Neurophysiological impairments in multiple sclerosis - central and peripheral motor pathways.
    Acta Neurol Scand. 2020 May 31. doi: 10.1111/ane.13289.
    PubMed     Abstract available

  47. ZANONI M, Orlandi E, Rossetti G, Turatti M, et al
    Up-regulated serum miR-128-3p in progressive and relapse-free multiple sclerosis patients.
    Acta Neurol Scand. 2020 May 20. doi: 10.1111/ane.13288.
    PubMed     Abstract available

  48. ZHU F, Shan W, Lv R, Li Z, et al
    Clinical characteristics of GAD 65 associated autoimmune encephalitis.
    Acta Neurol Scand. 2020 May 16. doi: 10.1111/ane.13281.
    PubMed     Abstract available

  49. COSTA ARPIN E, Naveiro Soneira J, Lema Bouzas M, Quintela AG, et al
    Epidemiology of multiple sclerosis IN Santiago de Compostela (Spain).
    Acta Neurol Scand. 2020 May 11. doi: 10.1111/ane.13265.
    PubMed     Abstract available

    April 2020
  50. CHOU CC, Huang MH, Lan WC, Kong SS, et al
    Prevalence and risk of thyroid diseases in myasthenia gravis.
    Acta Neurol Scand. 2020 Apr 23. doi: 10.1111/ane.13254.
    PubMed     Abstract available

    March 2020
  51. ZARGHAMI A, Nourmohammadi ST, Hojjati SMM
    Urbanization theory and socioeconomic changeover of multiple sclerosis in Iran.
    Acta Neurol Scand. 2020;141:256.

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.